RxDoctor Payments Data

Satyavardhan Pulukurthy, MD

Interventional Cardiology · Bremerton, WANPI 1902838154

Payments from drug & device makers

What this record shows

23 manufacturers reported payments, led by Medtronic at 33.8% of the total. Reporting peaked in 2024 at $3,650 and has fallen 73.7% since, to $961 in 2025.

$6,380in general payments, 2019–2025

Across 126 payments — averaging $50.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$2K
  • Boston Scientific$552
  • Penumbra, Inc.$506
  • Abiomed$413
  • E.r. Squibb & Sons, L.L.C.$167
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$2,55840%
  • Food & beverage$3,82260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,380 in reported general payments places this provider in the 60th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$691,568
Medicare patients
2,635
Services billed
9,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis23$529,503
EliquisApixaban306$410,709
JardianceEmpagliflozin279$368,750
EntrestoSacubitril/Valsartan186$266,331
XareltoRivaroxaban155$222,831
Repatha SureclickEvolocumab93$81,236
Repatha PushtronexEvolocumab47$29,001
BrilintaTicagrelor33$26,812
FarxigaDapagliflozin Propanediol18$24,627
Praluent PenAlirocumab34$19,863
Colesevelam Hcl21$11,536
Metoprolol Succinate712$10,544
Eplerenone72$7,244
ClopidogrelClopidogrel Bisulfate329$6,679
Ezetimibe245$6,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$24$940,212329 claims
NovartisEntresto$81$266,331186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Bremerton

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →